NCT04986878

Brief Summary

Adductor canal block (ACB) has emerged as an option for postoperative regional analgesia in patients undergoing total knee arthroplasty (TKA).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2017

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 15, 2017

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2018

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

June 30, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 3, 2021

Completed
Last Updated

August 4, 2021

Status Verified

August 1, 2021

Enrollment Period

1 year

First QC Date

June 30, 2021

Last Update Submit

August 3, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • postoperative pain scores by visual analogue score

    visual analogue score is a straight, vertical 10-cm line with the bottom point representing "no pain" = (0cm) and the top point representing "the worst pain you could ever have" = (10 cm).

    48 hours

Secondary Outcomes (3)

  • time to up and go test (minutes)

    48 hours

  • six-minute walking test

    48 hours

  • the 30-Second Chair test

    48 hours

Study Arms (2)

Single shot adductor canal block

ACTIVE COMPARATOR

Following sterile preparation and draping, an ultrasound survey of the medial thigh was performed, halfway between the superior anterior iliac spine and the patella. The superficial femoral artery has been identified beneath the sartorius muscle in a short-axis view, with the vein just inferior and the saphenous nerve just lateral to the artery. A 20 Gauge, 120 mm, non-cuttings tip echogenic needle (SonoPlex STIM, Germany) needle was introduced in-plane, and 2 to 3 mL of LA bolus (0.25 % Bupivacaine) was used to confirm proper needle placement in the adductor canal near the saphenous nerve. Then, a bolus of 20 ml of Bupivacaine 0.25 % was injected through the needle

Procedure: single-shot adductor canal block

Continuous adductor canal block

ACTIVE COMPARATOR

a catheter was secured in place using Tegaderm. The catheters were connected to a pump that infused local anesthetic, 20 mL of 0.25 % bupivacaine, followed by 48 hours of continuous infusion of 0.125 % bupivacaine at 5 mL/h.

Procedure: single-shot adductor canal block

Interventions

An ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe was used to perform the adductor canal block immediately postoperatively.

Also known as: Saphenous nerve block
Continuous adductor canal blockSingle shot adductor canal block

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients scheduled for primary total knee arthroplasty with
  • American Society of Anesthesiologists (ASA) physical status I -III,
  • mentally competent and able to give consent for enrollment in the study.

You may not qualify if:

  • Patient younger than 18 years old or older than 70 years old
  • Allergy to local anesthetics, systemic opioids (fentanyl, morphine, hydromorphone, and any of the drugs included in the multimodal perioperative pain protocol.
  • Revision surgeries were excluded.
  • Impaired kidney functions and patients with coagulopathy were also excluded.
  • Chronic pain syndromes and patients with chronic opioid use defined as the use of regular daily doses of systemic narcotics for the past 6 months prior to the surgery.
  • BMI of 40 or more
  • Pregnancy (positive urine pregnancy test result in Preop area on the morning of surgery)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Aswan University Hospital

Aswān, 81511, Egypt

Location

Huda Fahmy

Aswān, 81511, Egypt

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
A computer-generated randomization table will be used for patient allocation to one of the two study groups, The SACB group, and the CACB group. Randomization was done in blocks of 10 patients each. Patients' assignments were written in a sealed envelope that was only open after the patient consents to the study.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The target population of this study will be patients undergoing primary total knee arthroplasty at Aswan l and Assiut university hospitals
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor of Anesthesia and Intensive Care

Study Record Dates

First Submitted

June 30, 2021

First Posted

August 3, 2021

Study Start

March 15, 2017

Primary Completion

March 31, 2018

Study Completion

June 30, 2018

Last Updated

August 4, 2021

Record last verified: 2021-08

Locations